Familial combined hyperlipidemia

disorder

SNOMED 238040008CUI C0020474

Overview

Source: MedlinePlus.gov, National Library of Medicine. Not a substitute for medical advice.

Treatments & Interventions

Ezetimibe

substance

Mipomersen

substance

Mipomersen sodium

substance

Clinical Trials

Total Trials

Recruiting

With Results

Recent Trials

Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol

NCT00754039Phase 4Completed129 enrolled

View all 1 trials on ClinicalTrials.gov

Signs & Symptoms

Based on Human Phenotype Ontology (HPO) disease-phenotype annotations.

Elevated total cholesterol

Frequent (30-79%)HP:0003124

Xanthoma

Occasional (5-29%)HP:0001114

Arcus juvenilis

HP:0001084

Coronary disease

HP:0001677

Elevated circulating apolipoprotein A-II concentration

HP:0031800

Elevated circulating apolipoprotein B concentration

HP:0031798

Hyperlipidemia

HP:0003077

Increased circulating very-low-density lipoprotein levels

HP:0003362

Increased plasma LDL levels

HP:0003141

Myocardial infarction

HP:0001658

Related Conditions

Primary combined hyperlipidaemia(parent)

Quick Facts

SNOMED CT: 238040008
UMLS CUI: C0020474
Fully Specified Name: Familial combined hyperlipidemia (disorder)
Specialists: 0
Diagnostic Biomarkers: 0
HPO Phenotypes: 10
Known Treatments: 3
Clinical Trials: 1

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Clinical content is derived from the SNOMED CT clinical ontology and curated medical knowledge graphs.